ROKIT Healthcare Inc., a biotechnology company, provides hyper-personalized organ regenerative healthcare solutions in South Korea. The company offers skin regeneration therapy for the treatment of diabetic foot ulcers; cartilage regeneration delivers hyper-personalized therapeutic solutions for osteoarthritis patients; and kidney regeneration, a hyper-personalized treatment for chronic kidney disease (CKD). It also provides bioprinters; bioinks; Huma Media, a human adult stem cell culture media; HumaTein, a human cell-derived whole extracellular matrix; EpiTem, a reconstructed human epidermis model; and anti-aging supplements, as well as operates a tissue bank. The company was formerly known as ROKIT Inc. and changed its name to ROKIT Healthcare Inc. in 2018. The company was incorporated in 2012 and is based in Seoul, South Korea.
Metrics to compare | 376900 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship376900PeersSector | |
---|---|---|---|---|
P/E Ratio | −30.8x | −8.5x | −0.6x | |
PEG Ratio | 0.72 | −0.17 | 0.00 | |
Price/Book | −2.9x | 2.9x | 2.6x | |
Price / LTM Sales | 16.8x | 35.7x | 3.3x | |
Upside (Analyst Target) | - | 0.0% | 37.9% | |
Fair Value Upside | Unlock | 6.9% | 3.7% | Unlock |